How does capivasertib work (its mechanism of action)?
Capivasertib is a small-molecule inhibitor of the AKT pathway. It blocks the activity of AKT kinases (including AKT1, AKT2, and AKT3), which are key signaling proteins in the PI3K–AKT–mTOR network that drives cell growth and survival.[1]
By inhibiting AKT signaling, capivasertib can reduce downstream pro-survival and proliferation signals, which helps suppress tumor cell growth—especially in cancers where this pathway is abnormally activated (for example, due to alterations in PI3K/AKT or loss of PTEN). [1]
What pathway does capivasertib target downstream of PI3K?
Capivasertib acts downstream of PI3K within the PI3K–AKT–mTOR pathway. When PI3K activation increases AKT signaling, AKT then phosphorylates multiple downstream targets that support survival, metabolism, and proliferation. Blocking AKT interrupts that signaling cascade, lowering the output of the pathway’s growth and survival programs.[1]
What clinical tumor features make AKT inhibition relevant?
AKT inhibitors like capivasertib are used in settings where the PI3K–AKT pathway is dysregulated. Tumors with common upstream drivers (such as PI3K pathway alterations or PTEN loss) can depend on ongoing AKT signaling to survive and grow, so inhibiting AKT can be more effective than in tumors without pathway activation.[1]
How does AKT inhibition translate to antitumor effects?
Mechanistically, reducing AKT activity can shift signaling away from survival and proliferation programs, which can lead to decreased tumor cell growth and increased susceptibility to cell death pathways. The key driver is the disruption of AKT-dependent phosphorylation of downstream targets that normally help cancer cells persist under stress.[1]
Source
[1] https://www.drugpatentwatch.com/p/capivasertib